These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 19729196

  • 1. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
    Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ.
    Lancet; 2009 Sep 12; 374(9693):912-20. PubMed ID: 19729196
    [Abstract] [Full Text] [Related]

  • 2. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P, Haddad E, Albert MH, Hassan M, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation.
    Lancet; 2014 Feb 01; 383(9915):436-48. PubMed ID: 24161820
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA.
    Biol Blood Marrow Transplant; 2008 Nov 01; 14(11):1298-304. PubMed ID: 18940685
    [Abstract] [Full Text] [Related]

  • 4. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.
    Jacobsohn DA, Duerst R, Tse W, Kletzel M.
    Lancet; 2008 Nov 01; 364(9429):156-62. PubMed ID: 15246728
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.
    Biol Blood Marrow Transplant; 2006 Jul 01; 12(7):712-8. PubMed ID: 16785060
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.
    Bone Marrow Transplant; 2000 May 01; 25(10):1021-8. PubMed ID: 10828860
    [Abstract] [Full Text] [Related]

  • 7. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B.
    Biol Blood Marrow Transplant; 2012 Nov 01; 18(11):1656-63. PubMed ID: 22609040
    [Abstract] [Full Text] [Related]

  • 8. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A, Ngwube A, Hayashi R, Murray L, Davis J, Haut P, Loechelt BJ, Shenoy S.
    Biol Blood Marrow Transplant; 2015 Jul 01; 21(7):1321-5. PubMed ID: 25840334
    [Abstract] [Full Text] [Related]

  • 9. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, Kim SY, Lee YH, Lim YT, Yoo KH, Sung KW, Koo HH, Im HJ, Seo JJ, Park SK, Ahn HS, Korean Society of Pediatric Hematology-Oncology.
    Biol Blood Marrow Transplant; 2010 Nov 01; 16(11):1582-8. PubMed ID: 20685256
    [Abstract] [Full Text] [Related]

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 11. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, Bashey A.
    Biol Blood Marrow Transplant; 2014 Nov 01; 20(11):1828-34. PubMed ID: 25064745
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.
    Biol Blood Marrow Transplant; 2010 Jun 01; 16(6):818-23. PubMed ID: 20079864
    [Abstract] [Full Text] [Related]

  • 13. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, Ortin M, Freires M, Hale G, Waldmann H, Gordon-Smith EC, Marsh JC.
    Biol Blood Marrow Transplant; 2004 Dec 01; 10(12):867-76. PubMed ID: 15570255
    [Abstract] [Full Text] [Related]

  • 14. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S.
    Cytotherapy; 2001 Dec 01; 3(3):197-201. PubMed ID: 12171726
    [Abstract] [Full Text] [Related]

  • 15. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
    Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK.
    Bone Marrow Transplant; 2005 Jun 01; 35(12):1127-32. PubMed ID: 15834432
    [Abstract] [Full Text] [Related]

  • 16. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 01; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.
    Cytotherapy; 2001 Oct 01; 3(3):203-10. PubMed ID: 12171727
    [Abstract] [Full Text] [Related]

  • 18. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
    Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS.
    Bone Marrow Transplant; 2011 Jun 01; 46(6):790-9. PubMed ID: 20818441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.
    Bone Marrow Transplant; 2000 Sep 01; 26(6):615-20. PubMed ID: 11041566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.